Based in Calgary, Alberta, Psygen is a licensed pharmaceutical manufacturer of GMP-quality synthetic psychedelics, including psilocybin, LSD, MDMA and DMT. In recent years, an unprecedented demand for novel therapeutics has driven growth in this new sector.

Our investment in Psygen is an acknowledgement not just of the potential role that psychedelic medicine might play in the future of healthcare, but also of the steps necessary to operationalize that future as new legal mechanisms for access to these substances unfold.

Psygen is well-positioned to supply the clinical trials necessary to advance regulatory outcomes. From there, Psygen has the potential to secure ongoing supply agreements based on science-driven drug formulation goals from a wide variety of industry players, underpinning the development of this new sector.